About Cerebrolysin®

Cerebrolysin® is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment.
Cerebrolysin® improves the brain’s ability for self-repair by stimulating neurorecovery.
Cerebrolysin® is clinically proven and of European/Austrian quality.

Safety

Cerebrolysin® is safe and well tolerated!

The experience with Cerebrolysin® during many years of clinical application, the information from post-marketing surveillance studies, the safety data from double-blind, placebo-controlled clinical trials and EVER’s pharmacovigilance database demonstrate the excellent clinical safety profile of Cerebrolysin®.

According to EMA classification (European Medicines Agency), Cerebrolysin® is in the SAFE category. In general, reported adverse drug reactions are transient and mild in intensity.

Please note that the handling is very important.

You can get more information in the Dosage Card.

Prescribing information

Name of the medicinal product:
Cerebrolysin® - Solution for injection.
Qualitative and quantitative composition:
One ml contains 215.2 mg of Cerebrolysin® concentrate in aqueous solution.
List of excipients:
Sodium hydroxide and water for injection
Therapeutic indications:
For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer’s type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio).
Contraindications:
Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment.
Marketing Authorisation Holder:
EVER Neuro Pharma GmbH, A-4866 Unterach

Only available on prescription and in pharmacies
More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

This information is based on the Austrian Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local EVER representative.

How to use Cerebrolysin®

All relevant information about dosage, initiation and duration of treatment, route of administration can be found here.
Learn more

Mode of Action

Cerebrolysin® is a multimodal drug. 3-D Videos and a well structured booklet will show you all details about its MoA.
Learn more

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.